T2 Biosystems (TTOO) Competitors $0.11 -0.01 (-7.17%) As of 04/15/2025 03:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TTOO vs. PAVM, POAI, BSGM, NURO, INBS, DHAI, BLAC, BTCY, IINN, and LYRAShould you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include PAVmed (PAVM), Predictive Oncology (POAI), BioSig Technologies (BSGM), NeuroMetrix (NURO), Intelligent Bio Solutions (INBS), DIH Holding US (DHAI), Bellevue Life Sciences Acquisition (BLAC), Biotricity (BTCY), Inspira Technologies Oxy B.H.N. (IINN), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry. T2 Biosystems vs. PAVmed Predictive Oncology BioSig Technologies NeuroMetrix Intelligent Bio Solutions DIH Holding US Bellevue Life Sciences Acquisition Biotricity Inspira Technologies Oxy B.H.N. Lyra Therapeutics PAVmed (NASDAQ:PAVM) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk. Is PAVM or TTOO more profitable? PAVmed has a net margin of 602.97% compared to T2 Biosystems' net margin of -563.16%. Company Net Margins Return on Equity Return on Assets PAVmed602.97% N/A -92.36% T2 Biosystems -563.16%N/A -174.06% Does the MarketBeat Community prefer PAVM or TTOO? T2 Biosystems received 203 more outperform votes than PAVmed when rated by MarketBeat users. However, 66.12% of users gave PAVmed an outperform vote while only 62.56% of users gave T2 Biosystems an outperform vote. CompanyUnderperformOutperformPAVmedOutperform Votes20366.12% Underperform Votes10433.88% T2 BiosystemsOutperform Votes40662.56% Underperform Votes24337.44% Which has better earnings and valuation, PAVM or TTOO? T2 Biosystems has higher revenue and earnings than PAVmed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPAVmed$3.00M4.08-$64.18M-$2.25-0.32T2 Biosystems$7.68M0.30-$50.08MN/AN/A Do insiders and institutionals have more ownership in PAVM or TTOO? 19.9% of PAVmed shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 11.3% of PAVmed shares are held by insiders. Comparatively, 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate PAVM or TTOO? PAVmed currently has a consensus price target of $19.00, suggesting a potential upside of 2,556.23%. T2 Biosystems has a consensus price target of $5.00, suggesting a potential upside of 4,445.45%. Given T2 Biosystems' higher possible upside, analysts plainly believe T2 Biosystems is more favorable than PAVmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50T2 Biosystems 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor PAVM or TTOO? In the previous week, PAVmed had 7 more articles in the media than T2 Biosystems. MarketBeat recorded 8 mentions for PAVmed and 1 mentions for T2 Biosystems. PAVmed's average media sentiment score of 0.19 beat T2 Biosystems' score of 0.00 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral T2 Biosystems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PAVM or TTOO? PAVmed has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. SummaryPAVmed beats T2 Biosystems on 11 of the 16 factors compared between the two stocks. Remove Ads Get T2 Biosystems News Delivered to You Automatically Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTOO vs. The Competition Export to ExcelMetricT2 BiosystemsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.23M$4.07B$5.32B$7.56BDividend YieldN/A39.50%5.11%4.33%P/E RatioN/A27.6221.7717.81Price / Sales0.2947.55378.2693.59Price / CashN/A51.0838.1534.64Price / Book-0.025.826.443.99Net Income-$50.08M$67.09M$3.20B$247.23M7 Day PerformanceN/A5.89%6.42%7.24%1 Month Performance-15.20%-3.03%-8.66%-6.26%1 Year Performance-96.43%14.50%10.27%-0.18% T2 Biosystems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTOOT2 BiosystemsN/A$0.11-7.2%$5.00+4,445.5%-96.3%$2.32M$7.68M0.00180Gap DownPAVMPAVmed3.9758 of 5 stars$0.60+0.8%$19.00+3,066.7%-62.5%$10.07M$3.00M-0.1490Short Interest ↑POAIPredictive Oncology1.6836 of 5 stars$1.11-17.2%$3.00+170.3%-35.3%$9.92M$1.62M-0.3630Short Interest ↑Gap DownBSGMBioSig Technologies1.9088 of 5 stars$0.53+2.9%$2.75+418.9%-46.4%$9.14M$39,000.000.0050NURONeuroMetrix1.0876 of 5 stars$4.38-0.7%N/A+23.5%$9.02M$3.03M-0.9520Analyst ForecastShort Interest ↓Gap DownINBSIntelligent Bio Solutions0.2527 of 5 stars$1.32-2.2%N/A-61.3%$8.96M$3.03M0.0010Short Interest ↑DHAIDIH Holding US1.2656 of 5 stars$0.18-0.8%N/A-86.0%$8.52M$64.47M-0.60N/ANews CoverageGap DownHigh Trading VolumeBLACBellevue Life Sciences AcquisitionN/A$1.95-21.1%N/A-86.5%$7.88MN/A0.00N/AGap DownHigh Trading VolumeBTCYBiotricityN/A$0.31-12.1%N/A-69.0%$7.66M$12.06M-0.2840Gap DownIINNInspira Technologies Oxy B.H.N.1.1099 of 5 stars$0.60+1.3%N/A-68.5%$7.55MN/A0.0020Short Interest ↓News CoverageGap DownLYRALyra Therapeutics2.6287 of 5 stars$0.11-7.2%$1.25+1,017.1%-98.3%$7.37M$1.53M-0.0850Negative News Remove Ads Related Companies and Tools Related Companies PAVmed Competitors Predictive Oncology Competitors BioSig Technologies Competitors NeuroMetrix Competitors Intelligent Bio Solutions Competitors DIH Holding US Competitors Bellevue Life Sciences Acquisition Competitors Biotricity Competitors Inspira Technologies Oxy B.H.N. Competitors Lyra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTOO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share T2 Biosystems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TTOO Stock Free TTOO Stock Alerts